A Phase I Dose Escalation Study of Continuous Oral OSI-906 Dosing in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Linsitinib (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Astellas Pharma
- 17 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Nov 2011 Company (Astellas Pharma) added as reported by ClinicalTrials.gov.
- 08 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.